ChiCTR-IOR-17012630
尚未开始
/
/
/
2017-09-04
/
/
肩部肌腱炎
肩胛骨訓練計劃對患有肩部肌腱炎的病人之效能
肩胛骨訓練計劃對患有肩部肌腱炎的病人之效能
肩胛骨訓練計劃對患有肩部肌腱炎的病人之效能
随机平行对照
其它
Randomized controlled trial
Double-blind
No
/
62
/
1990-01-01
1990-01-01
/
Presence of shoulder pain for more than 3 months 3 out of 5 positive tests (painful arc, resisted external rotation, Neer test, Kennedy-Hawkins test and Jobe test). The intensity of pain being provoked should be ≥ 3/10 on a visual analogue scale (VAS) from 0 to 10, with 0 indicating no pain, and 10 indicating the worst pain Obvious scapular dyskinesis while the participant’s performing 5 repetition of weighted shoulder flexion according to their body weight (3lb for weight <150lb; 5lb for those > 150lb) (Clarsen et al. 2014) Ultrasound image showed pathological changes of the supraspinatus tendon (Leong et al. 2016b), and the severity of pathological changes will be graded (Tsui et al. 2017);
请登录查看Full-thickness tear of the rotator cuff tendon Shoulder dislocation or instability; Labral tears; Frozen shoulders; Symptoms referred from or related to the spine; History of shoulder fractures; Previous shoulder surgery a shoulder injury; Previous clinical treatment for a shoulder injury within the last 12 months.;
请登录查看Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong
/
Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong的其他临床试验
Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

